Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · TelehealthDirect-to-consumer TelehealthVirtual CareHealth Plans
Share
Learn this in 60 seconds

Key facts, context, and what it means, in one minute.

:60
0:001:00
Direct-to-consumer telehealth raises spending, even as ASC investment surges

Key takeaways

01

The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.

02

The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Direct-to-consumer telehealth has been sold to employers and health plans for a decade on a simple promise: swap expensive office and emergency department visits for a cheaper virtual visit. The best-cited public claims benchmark says that swap often doesn’t happen.

In an analysis published by Health Affairs, researchers used commercial claims data covering more than 300,000 patients across 2011, 13 and focused on acute respiratory illnesses. They estimated that 12% of direct-to-consumer telehealth visits replaced visits to other providers, while 88% represented new utilization. Net annual spending on acute respiratory illness increased by $45 per telehealth user, according to the Health Affairs abstract.

The number operators can actually plan around: 12% substitution

For benefit and network leaders, the most actionable part of the Health Affairs result is not the $45 figure, it’s the substitution math behind it. A virtual channel that replaces 12% of visits behaves very differently in forecasting than one that replaces 50%.

That distinction matters because many internal dashboards still treat telehealth success as “adoption,” measured by registrations, utilization, or member satisfaction. According to Health Affairs, increased convenience may tap into unmet demand for health care, and new utilization may increase overall health care spending. In 2011, 13 claims data on acute respiratory illnesses, Health Affairs estimated that 12 percent of direct-to-consumer telehealth visits replaced visits to other providers and 88 percent represented new utilization, with net annual spending increasing $45 per telehealth user.

ASC investment is rising, and it changes what “downstream” means

MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

For operators, the connection is practical. As outpatient capacity expands, virtual front doors increasingly act as the routing layer: who gets scheduled where, in what timeframe, and under which benefit incentives. Telehealth ROI can hinge on whether the virtual workflow is wired into the ASC network’s scheduling, prior authorization checks, and referral management, instead of simply creating a new entry point that generates more appointments.

If convenience is the product, triage and steering have to be the controls.

What to change in benefit design and vendor scorecards

The Health Affairs findings don’t say direct-to-consumer telehealth is “bad.” According to Health Affairs, increased convenience may tap into unmet demand for health care, and new utilization may increase overall health care spending. The operational job is to decide when incremental care is a feature, improved access, and when it’s leakage that should be redirected or deflected.

Where this lands in 2027 planning for payers and large employers

  • Use substitution versus new utilization as the core measure when evaluating direct-to-consumer telehealth. Health Affairs estimated that 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization in an acute respiratory illness claims analysis.
  • Align incentives to the channel’s job. If telehealth is intended to replace physician office, urgent care, or emergency department visits, confirm the benefit differential, after-hours coverage, and triage pathways that make substitution plausible, not just convenient.
  • If your network strategy includes ASCs, map the referral and scheduling handoff from virtual visits into your preferred outpatient sites. MobiHealthNews’ reporting on ambulatory surgery center investment is a reminder that outpatient capacity and competition can shape where care flows.
  • Track utilization and spending, not just per-visit prices. Health Affairs reported net annual spending on acute respiratory illness increased $45 per telehealth user in its analysis, which can be missed if results are only reviewed in overall averages.

Featured companies

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

Interchangeable biosimilars cut drug spend only when pharmacies can actually switch them

The FDA’s interchangeable biosimilar pathway is moving from a one-off insulin milestone to a repeatable playbook for pharmacy-level substitution, with Wezlana (ustekinumab-auub) approved as interchangeable to Stelara in late 2023 and a first interchangeable biosimilar to golimumab reported in September 2026. Evidence from a JAMA Health Forum economic evaluation cited by Podiatry Today found that insulin glargine interchangeability in November 2021 was followed by an immediate jump of more than 47,000 prescriptions for Semglee and insulin glargine-yfgn, suggesting the designation itself can change dispensing behavior. For hospitals, health systems, and payers, the operational consequence shows up less in the FDA letter and more in formulary design, NDC-level claims logic, pharmacy notification requirements that vary by state, and the inventory and education workflows that make substitution predictable instead of chaotic.

  • 01Interchangeability is a workflow change, not a clinical debate. The systems that decide spend are NDC mapping, e-prescribe defaults, and pharmacy switch rules governed by state law.
  • 02The pipeline is widening beyond diabetes. Wezlana’s interchangeability to Stelara (Healthcare Purchasing News) and a newly reported interchangeable golimumab biosimilar (Journal of Healthcare Management/AJN via Ovid) signal more specialty and infusion-adjacent categories will face pharmacy-level substitution decisions.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512